Nattokinase Studies: What the Research Says

You've seen the claims — nattokinase dissolves blood clots, reverses plaque, lowers blood pressure. Social media threads and health forums are full of people crediting this fermented soybean enzyme with everything from preventing strokes to replacing blood thinners. But when you search for actual nattokinase studies, what you find is a wall of academic papers that are hard to parse and a handful of consumer articles that either oversimplify or oversell.

So what does the clinical research actually show? The answer is more nuanced than most sources let on. Some benefits are backed by meta-analyses of randomized controlled trials. Others rest on a single observational study. And a few popular claims have no clinical evidence behind them at all.

We reviewed over 20 peer-reviewed studies — including meta-analyses, randomized controlled trials, safety assessments, and Japanese-language research from J-STAGE — to give you a clear, honest synthesis of the nattokinase evidence. This guide is organized by evidence quality so you can evaluate each benefit for yourself and have an informed conversation with your healthcare provider.

What Is Nattokinase?

Nattokinase is a serine protease enzyme produced during the fermentation of soybeans into natto, a traditional Japanese food with a distinctively sticky texture ^[6]. It was discovered in 1980 by Dr. Hiroyuki Sumi at what is now Kurashiki University of Science and the Arts, when he observed that natto could dissolve artificial blood clots (fibrin) in a laboratory setting ^[16].

The enzyme has a molecular weight of approximately 27.7 kDa and its activity is measured in fibrinolytic units (FU) — the standard unit for quantifying clot-dissolving capacity ^[6]. An important distinction: nattokinase is not the same as natto itself. Natto contains multiple bioactive components including vitamin K2, polyamines, and probiotics alongside nattokinase ^[17]. Nattokinase supplements typically isolate the enzyme and remove vitamin K2 — a critical difference for people on anticoagulant medications.

How Nattokinase Works: Mechanism of Action

Fibrinolytic Activity

Nattokinase dissolves blood clots through multiple pathways, not just one ^[1][4]:

• Direct fibrinolysis: Nattokinase directly degrades cross-linked fibrin, the structural protein that holds blood clots together
• tPA activation: It enhances the body's own clot-dissolving system by increasing tissue plasminogen activator (tPA) activity
• PAI-1 suppression: It reduces plasminogen activator inhibitor-1, effectively removing the brake on natural fibrinolysis
• Coagulation factor reduction: It lowers levels of factors VII and VIII, as well as plasma fibrinogen

The fibrinolytic potency of nattokinase is approximately 4x that of plasmin — the body's primary clot-dissolving enzyme. It also has a hemorrhagic safety margin roughly 3x higher than tissue plasminogen activator (tPA), the pharmaceutical thrombolytic drug ^[1][2].

Anti-Inflammatory and Antioxidant Effects

Beyond fibrinolysis, emerging evidence suggests nattokinase suppresses NF-kB signaling and reduces inflammatory cytokines — pathways involved in atherosclerosis development ^[8]. Antioxidant properties that may protect vascular endothelium have also been reported, though this evidence is still preliminary ^[8].

Bioavailability

A practical question for any oral supplement: does it actually survive digestion? Evidence indicates nattokinase is absorbed intact through the intestinal tract. A single oral dose of 2,000 FU has been shown to increase fibrin degradation products in plasma within 4 hours ^[4]. Enteric-coated capsules can further improve bioavailability by protecting the enzyme from stomach acid degradation ^[6][16].

Key Clinical Studies on Nattokinase

Before diving into each benefit area, here is an overview of the most important clinical studies on nattokinase. This table lets you compare study designs, sample sizes, and findings at a glance.

Blood Pressure Studies: Strong Evidence

Blood pressure reduction is the best-supported benefit of nattokinase, backed by the highest level of evidence — a meta-analysis of randomized controlled trials.

Meta-Analysis Results

A systematic review and meta-analysis pooling data from 6 RCTs with 546 total participants found nattokinase supplementation significantly reduced ^[1]:

• Systolic blood pressure: -3.45 mmHg (95% CI: -4.37 to -2.18, p < 0.00001)
• Diastolic blood pressure: -2.32 mmHg (p < 0.00001)
• No notable adverse events reported in any included trial

Putting the Numbers in Context

A 3.45 mmHg systolic reduction is clinically modest but meaningful at a population level. For comparison:

Nattokinase is not a replacement for blood pressure medication, but the evidence supports it as a modest adjunct — particularly relevant for those with mildly elevated blood pressure who may not yet require pharmaceutical intervention.

Supporting Trial

A randomized, double-blind, placebo-controlled, multicenter trial conducted in North America confirmed that nattokinase supplementation was associated with reduced blood pressure and significantly lower von Willebrand factor (vWF), a cardiovascular risk marker ^[5]. This is one of the most-cited nattokinase trials, with 96 citations in the academic literature.

Atherosclerosis and Plaque Studies: Mixed Evidence

This is where the nattokinase evidence gets complicated — and where honest reporting matters most. Two major studies reached opposite conclusions.

The Positive Study: 36% Plaque Reduction

A large observational study followed 1,062 participants with atherosclerosis and hyperlipidemia for 12 months ^[13]. After nattokinase consumption:

• Carotid artery intima-media thickness (CCA-IMT) decreased from 1.33 to 1.04 mm (p < 0.001)
• Carotid plaque size decreased by approximately 36%
• Total cholesterol, LDL, and triglycerides also improved

A separate review noted that 26 weeks of 6,500 FU/day showed significant reduction in CCA-IMT and plaque size, with results greater than simvastatin 20 mg/day ^[4].

The Null Result: NAPS Trial

The Nattokinase Atherothrombotic Prevention Study (NAPS) — the first large-scale, long-term RCT — followed healthy adults for 3 years ^[3]:

• Annualized carotid IMT progression: 0.013 mm/year (nattokinase) vs 0.011 mm/year (placebo)
• No significant difference (p = 0.31)
• No difference in arterial stiffness

What Explains the Discrepancy?

The key difference is the study population. The observational study enrolled patients with existing atherosclerosis (secondary prevention), while the NAPS trial enrolled healthy adults (primary prevention). Nattokinase may be more effective in people who already have atherosclerotic changes — but this hypothesis needs confirmation through randomized trials in at-risk populations.

The bottom line: The 36% plaque reduction headline is real, but it comes from a non-randomized study. The most rigorous RCT found no benefit in healthy people. If you have existing cardiovascular disease, discuss nattokinase with your cardiologist. If you are healthy, do not rely on nattokinase for plaque prevention based on current evidence.

Blood Clot and Fibrinolytic Studies: Moderate Evidence

Nattokinase's clot-dissolving properties are its most well-characterized benefit, supported by both laboratory evidence and clinical trials — though the evidence has important limitations.

What the Trials Show

An open-label RCT using doses of 2,000-6,500 FU found nattokinase reduced fibrinogen and coagulation factors VII and VIII (p < 0.05). A single 2,000 FU dose increased fibrin/fibrinogen degradation products within 4 hours (p < 0.05) ^[4].

A trial in patients with stable coronary artery disease tested nattokinase combined with red yeast rice over 90 days ^[7]. The combination:

• Reduced thromboxane B2 (TXB2) (p = 0.009 vs placebo)
• Increased antithrombin III (AT-III) (p = 0.0038 vs placebo)
• Produced no adverse events even with concurrent heart medications

A comprehensive review with 262 citations concluded nattokinase is an effective oral antithrombotic agent, with fibrinolytic activity persisting for 8-12 hours after a single oral dose ^[6].

The Critical Limitation

Nattokinase clearly affects fibrinolytic biomarkers — it changes measurable blood parameters related to clotting. But preventing actual clinical events (strokes, DVTs, heart attacks) has not been demonstrated in clinical trials. A comparison with novel oral anticoagulants (NOACs) confirmed that while nattokinase shows promise, it lacks the Phase III trial data that pharmaceutical anticoagulants have ^[9]. Nattokinase is not a substitute for prescribed blood thinners.

Cholesterol and Lipid Studies: Inconsistent Evidence

If you have read that nattokinase lowers cholesterol, the evidence may surprise you.

What the Meta-Analysis Found

The same meta-analysis that confirmed blood pressure benefits found the opposite for cholesterol ^[1]:

• Low-dose nattokinase: slightly increased total cholesterol (MD = 5.27 mg/dL, p < 0.00001)
• High-dose nattokinase: also slightly increased total cholesterol (MD = 3.18 mg/dL, p < 0.00001)
• No significant effect on HDL, LDL, or triglycerides (p > 0.05)

Conflicting Individual Studies

The large observational study of 1,062 participants did show reductions in total cholesterol, LDL, and triglycerides over 12 months ^[13]. However, this was an open-label, non-randomized design — a lower level of evidence than the meta-analysis.

When nattokinase was combined with Monascus (red yeast rice) in a 4-month RCT, lipid markers improved ^[15]. But the lipid-lowering effect was likely driven by monacolin K (a naturally occurring statin) in the red yeast rice rather than nattokinase itself.

A comprehensive review of nattokinase's lipid effects concluded that evidence is inconsistent and difficult to form consensus through meta-analysis ^[11].

The bottom line: Do not take nattokinase primarily for cholesterol management. Its primary cardiovascular effects are on blood pressure and fibrinolysis, not lipid levels.

Nattokinase Dosage: What Clinical Trials Used

There is no single established dose — different studies have tested different amounts for different outcomes. Here is what the clinical trials used:

Most commonly effective range: 2,000-6,500 FU/day. Blood pressure effects have been observed at lower doses (2,000-4,000 FU/day), while plaque-related effects were studied at higher doses (6,500 FU/day). GLP-compliant toxicology testing in animal models found nattokinase was nonmutagenic and nonclastogenic at doses 100-1,000x higher than recommended human doses ^[12].

When to expect results: Blood pressure effects may appear within 4-8 weeks based on trial durations. Any effects on plaque were observed over 6-12 months. A single dose produces measurable fibrinolytic changes within 4 hours, with effects lasting 8-12 hours.

Safety Considerations

Side Effects Reported in Clinical Trials

The safety profile of nattokinase in clinical trials is reassuring. The meta-analysis of RCTs reported no notable adverse events in any nattokinase or placebo group, with compliance rates exceeding 95% ^[1].

A real-world safety study followed 153 patients (ages 22-92) with vascular diseases and found no adverse drug reactions and no drug interactions during the follow-up period ^[14]. When side effects did occur across studies, they were primarily mild skin manifestations and gastrointestinal symptoms — reported at a rate of 4.65% in nattokinase groups compared to 5.56% in control groups, a difference that was not statistically significant ^[14].

Drug Interactions

This is the most critical safety consideration for nattokinase:

Nattokinase adds fibrinolytic activity on top of anticoagulant effects — a combination that theoretically increases bleeding risk. One observational study did successfully combine nattokinase with enoxaparin (a heparin) in phlebitis patients without adverse events, but this should not be generalized ^[14].

Who Should Avoid Nattokinase

• People with bleeding disorders — nattokinase's fibrinolytic activity could worsen bleeding
• Pre-surgery patients — discontinue at least 2 weeks before any scheduled surgery
• Anyone on anticoagulant therapy without medical supervision — the combination is high-risk
• Active bleeding — contraindicated

Pregnancy and Nursing

No pregnancy-specific safety data exists for nattokinase. Given its fibrinolytic mechanism, nattokinase should be avoided during pregnancy and nursing until safety data becomes available. This is a significant gap in the evidence ^[2].

Realistic Expectations

Nattokinase is a dietary supplement, not a medication ^[9]. Important realities:

• Blood pressure effects are modest (~3.5 mmHg systolic) — roughly one-quarter to one-third of a standard antihypertensive
• Plaque effects are uncertain — one positive observational study vs one null RCT
• Fibrinolytic biomarker changes are demonstrated, but prevention of strokes, DVTs, or heart attacks is not proven
• Lipid effects are inconsistent — nattokinase is not a reliable cholesterol-lowering agent
• It should never replace prescribed cardiovascular medications without your doctor's guidance

From the Japanese Research: What Most Guides Miss

Nattokinase has its roots in Japanese food science, and the Japanese research landscape offers insights that rarely appear in English-language guides. Here are the most significant.

The Natto Paradox: Food vs. Supplement Research

Japanese research has long studied natto as a whole food — not just the isolated enzyme. Epidemiological studies show that regular natto consumption is associated with reduced cardiovascular mortality in Japanese populations ^[2]. But natto contains much more than nattokinase: vitamin K2 (which supports bone and vascular health), polyamines, probiotics, and other bioactive compounds ^[17].

This creates a research paradox. The cardiovascular benefits observed in Japanese natto-eating populations may come from the whole food matrix, not nattokinase alone. Most international clinical trials test isolated nattokinase supplements — a fundamentally different intervention. When evaluating nattokinase studies, this distinction matters.

Why this matters: If you are taking nattokinase primarily for cardiovascular support, the Japanese food-science perspective suggests that a whole-food approach (consuming natto itself) may offer broader benefits than an isolated enzyme supplement. However, supplements provide standardized dosing that food cannot.

JNKA Certification: A Quality Standard With No International Equivalent

The Japan Nattokinase Association (JNKA) operates a quality certification program for nattokinase products — verifying enzyme content, purity, and manufacturing standards ^[19]. No equivalent certification program exists in international supplement markets.

This matters because nattokinase supplement quality varies widely. FU counts on labels do not always match actual enzyme activity, and manufacturing processes affect bioavailability. JNKA-certified products have been independently verified, providing an objective quality signal.

Why this matters: When choosing a nattokinase supplement, JNKA certification offers a reliability indicator that third-party testing in other markets does not replicate at the same specificity.

Japanese Regulatory Framework for Functional Foods

Japan's 機能性表示食品 (Foods with Function Claims) system allows manufacturers to make specific health claims — such as blood flow improvement — based on evidence submissions reviewed by the Consumer Affairs Agency (消費者庁) ^[19]. This is more structured than the U.S. Dietary Supplement Health and Education Act (DSHEA) framework, which does not require pre-market evidence review for supplements.

Japan is also the world's largest nattokinase market, valued at approximately 30 billion yen. Decades of safe population-level natto consumption provide real-world safety data at a scale that clinical trials alone cannot match ^[19].

Why this matters: Japanese regulatory infrastructure and market maturity mean that nattokinase products from Japan have undergone more scrutiny than many international alternatives. This does not guarantee superiority, but it provides a more developed quality assurance framework.

Foundational Research That Doesn't Appear in English Reviews

Dr. Sumi's original J-STAGE publications on nattokinase's fibrinolytic mechanism remain foundational to the field but are rarely cited in English-language consumer guides ^[16]. Japanese pharmacology reviews have also examined nattokinase alongside other functional foods with antihypertensive properties, placing it within a broader Japanese tradition of studying food-derived bioactive compounds ^[18].

A recent Japanese study on natto fermentation and health functions continues this tradition, exploring how fermentation conditions affect bioactive compound production — research that informs manufacturing processes for higher-quality nattokinase supplements ^[17].

Why this matters: The Japanese research tradition approaches nattokinase from a food science and fermentation perspective, not just a pharmaceutical one. This produces insights about optimal formulation and manufacturing that purely clinical-trial-focused research misses.

Our Recommendations

Japanese Nattokinase 4000

Why We Selected This: This is our primary recommendation for readers interested in nattokinase based on the research reviewed in this article. From a trusted Japanese manufacturer, this supplement delivers 4,000 FU per serving — within the dosage range shown to reduce blood pressure in clinical trials (2,000-4,000 FU/day). The high FU count per capsule means fewer capsules needed daily, and Japanese manufacturing standards provide quality assurance that aligns with the JNKA-certified market we discussed above.

View Japanese Nattokinase 4000 →

Nattokinase EX

Why We Selected This: For those specifically focused on cardiovascular support, Nattokinase EX is formulated with a cardiovascular health emphasis. It offers a complementary option for readers whose primary interest is circulatory function rather than general nattokinase supplementation. Japanese quality standards and manufacturing practices apply.

View Nattokinase EX →

Noguchi Nattokinase HQ

Why We Selected This: Noguchi is a well-established Japanese supplement brand, and their Nattokinase HQ provides a premium formulation focused on purity and bioavailability. This is a strong alternative for readers who prioritize brand heritage and manufacturing transparency.

View Noguchi Nattokinase HQ →

Conclusion

The clinical evidence on nattokinase is genuinely promising in some areas and genuinely uncertain in others. Blood pressure reduction is the strongest finding, supported by a meta-analysis showing a modest but significant ~3.5 mmHg systolic decrease. Fibrinolytic activity is well-demonstrated at the biomarker level. But plaque reduction evidence is mixed, lipid-lowering effects are inconsistent, and prevention of clinical cardiovascular events remains unproven.

What makes nattokinase particularly interesting from an evidence perspective is the depth of Japanese research that most English-language guides miss — from Dr. Sumi's foundational work to the JNKA quality certification system to the regulatory framework that allows evidence-based health claims.

For those considering nattokinase, Japanese-manufactured supplements with verified FU counts offer the most reliable starting point. But the single most important step is a conversation with your healthcare provider — especially if you take any cardiovascular medications.

This article is for informational purposes only and does not constitute medical advice. Consult a healthcare professional before starting any new health regimen, especially if you have existing health conditions or take medications. Statements about dietary supplements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.